ANCHOR LEAD: A DRUG THAT’S PROVEN USEFUL AGAINST TWO TYPES OF CANCER MAY BE HELPFUL IN OTHERS, ELIZABETH TRACEY REPORTS
Inhibition of an important pathway of both normal embryogenesis and at least two types of cancer called hedgehog is possible with an experimental drug known as GDC-0449. Charles Rudin, a cancer expert and lead author of two recent studies assessing the drug’s efficacy, says the results encourage expanded use in other tumor types.
RUDIN: What we’re interested in in the next phase of this research is to look at whether this drug may have activity more broadly in other solid tumors. We think that this drug is not going to have single agent activity in those types of cancers but it may selective activity against cancer regrowth, if we combine it with a standard cytotoxic therapy that kills the bulk of tumor cells, we may improve the long term prognosis for patients with cancer by preventing recurrent disease. :32
Rudin says genetic analysis may predict which tumors will likely respond. At Johns Hopkins, I’m Elizabeth Tracey.